US FDA’s Breakthrough Program Needs Higher Standard For Comparators, NEJM Says image

Pink Sheet, April 11, 2018
Michael Cipriano, quoting Jonathan Darrow (Student Fellow Alumnus)

Links

Read the Full Article (Paywall)

This article is behind a paywall. Readers will have to pay for full access to the article. 

Executive Summary

Harvard Medical School researchers call for inclusion of off-label drugs, accelerated approvals, and dietary supplements in the definition of 'existing therapies.'

Read the full article here!

health law policy